Psychopharmacology and Psychiatry Updates

In this episode, we explore evidence-based pharmacotherapy for bulimia nervosa, including why higher doses of SSRIs work better than standard dosing, which medications to avoid completely, and how antidepressants can be effective even without depression being present. Why does fluoxetine require 60 mg daily for optimal results? Faculty: Scott Crow M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Pharmacotherapy of Eating Disorders: An Update Bulimia Nervosa: Medications That Work

In this episode, we explore groundbreaking research on managing antipsychotic-induced weight gain through a comprehensive network meta-analysis. Could the combination of low-dose metformin and lifestyle modifications be the game-changer that helps patients maintain both mental stability and physical health? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 71 Antipsychotic-Induced Weight Gain: Best Management Strategies

In this episode, we explore extended-release naltrexone for opioid use disorder, examining its unique role as a pure antagonist in patients who require safety-sensitive careers. How do we successfully navigate the challenging initiation period when patients must be opioid-free for a week? Faculty: Smita Das, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Pharmacologic Management of Opioid Use Disorder Examining the Efficacy of Extended-Release Naltrexone OUD

In this discussion, Scott Beach, an expert on antipsychotic medications and their risks, highlights the unexpected link between antipsychotics and increased pneumonia risk in schizophrenia patients. He breaks down the significant role of anticholinergic burden and how certain medications, especially at high doses, can exacerbate this risk. The conversation emphasizes the need for careful monitoring and tailored treatment strategies to protect vulnerable patients, particularly the elderly, in managing their mental health.

In this episode, we explore how to choose between methadone, buprenorphine, and naltrexone for opioid use disorder treatment. With over 100,000 overdose deaths annually, how do we match the right medication to save each patient's life? Faculty: Smita Das, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Pharmacologic Management of Opioid Use Disorder Tailored Patient Assessment: A Key to Effective OUD Treatment  

In this episode, we explore buprenorphine management for opioid use disorder, covering induction protocols, dosing strategies, and long-term maintenance. Why do patients need to be in withdrawal before starting this life-saving medication, and how can we make this challenging process more manageable? Faculty: Smita Das, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Pharmacologic Management of Opioid Use Disorder Buprenorphine for Managing OUD

Dr. Paul Zarkowski, a leading expert in psychopharmacology, dives into the intriguing relationship between valproate dosage and weight gain. He discusses groundbreaking research suggesting that lower doses might preserve therapeutic effects while reducing this common side effect. The conversation emphasizes the importance of early weight monitoring in treatment and how individual patient factors like gender and BMI play a crucial role. This fresh perspective could revolutionize prescribing practices for those using valproate.

In this episode, we explore methadone maintenance therapy for opioid use disorder, covering dosing strategies, recent regulatory changes, and safety considerations. Why do so many patients fail on methadone despite its proven effectiveness, and how can proper dosing make the difference between recovery and relapse? Faculty: Smita Das, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Pharmacologic Management of Opioid Use Disorder Methadone for Managing OUD

Oliver Freudenreich, a psychiatrist from Boston, dives into the complex relationship between clozapine and obsessive-compulsive symptoms in schizophrenia. He discusses recent research highlighting whether clozapine triggers OCD or if there are deeper psychological mechanisms involved. The conversation covers the prevalence of OCD-like symptoms in clozapine users, the distinction between psychosis and compulsive behaviors, and tailored treatment strategies for improving patient outcomes. With engaging case studies, the episode unpacks the challenges of managing these intertwined symptoms.

This discussion delves into the rising concern of alcohol use disorder in the U.S. Both naltrexone and topiramate are examined for their roles in treatment, revealing intriguing findings that suggest they might be equally effective. Genetic factors are considered for personalized recovery strategies. With topiramate emerging as a promising option, listeners explore whether it could serve as an effective alternative to the FDA-approved medication. The implications for patient care and individualized treatment decisions are emphasized throughout.